Bayesian network analyses of resistance pathways against efavirenz and nevirapine-Reference-Cited by-同舟云学术

Bayesian network analyses of resistance pathways against efavirenz and nevirapine

Published:2008-10-18 Issue:16 Volume:22 Page:2107-2115
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Deforche Koen,Camacho Ricardo J,Grossman Zehave,Soares Marcelo A,Van Laethem Kristel,Katzenstein David A,Harrigan P Richard,Kantor Rami,Shafer Robert,Vandamme Anne-Mieke

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference30 articles.

1. Genotypic testing for human immunodeficiency virus type 1 drug resistance;Shafer;Clin Microbiol Rev,2002

2. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients;Van Laethem;Antivir Ther,2002

3. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients;Frater;AIDS,2001

4. Antiretroviral drug resistance in nonsubtype B HIV-1, HIV-2 and SIV;Parkin;Antivir Ther,2004

5. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy;Brindeiro;J Clin Microbiol,2002

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C;PLOS Computational Biology;2021-09-07

2. Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C;2020-09-25

3. VIRULIGN: fast codon-correct alignment and annotation of viral genomes;2018-09-06

4. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning;Infection, Genetics and Evolution;2017-09

5. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial;Infection, Genetics and Evolution;2016-10